RESULTS FROM THE GERMAN BACLAD CLINICAL TRIAL AND ADDITIONAL NEUROIMAGING RESULTS

admin isbra esbra

Müller CA1, Geisel O1, Pelz P1, Higl V1, Krüger J1, Stickel A1, Beck A1, Wernecke KD2, Hellweg R1, Heinz A1

1Department of Psychiatry, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany

2Charité – Universitätsmedizin Berlin and Sostana GmbH Berlin, Germany

Previous clinical studies using low dosages of the selective GABA-B receptor agonist baclofen (30-80 mg/d) in alcohol-dependent patients reported divergent results. Preclinical as well as clinical findings suggested a dose-dependent effect of baclofen in modulating alcohol-related behaviors. The BACLAD trial aimed to evaluate the efficacy and safety of individually titrated high-dose baclofen (up to 270 mg/d) for the treatment of alcohol dependence using a randomized, placebo-controlled design. We found that high-dose treatment with baclofen effectively supported alcohol-dependent patients in maintaining abstinence. The medication was well tolerated and no drug-related serious adverse events were observed. In addition to these results, neuroimaging findings concerning the effects of baclofen on neural correlates of alcohol dependence will be presented.